Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25%(Alcaftadine) for the Prevention of Itching Associated with Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea

First published 14/12/2016

Last updated 02/07/2024

EU PAS number:

EUPAS16675

Study

Finalised

Documents

Study protocol

Initial protocol

Protocol 229666-007 PMS Korea Amd 2 FINAL 28Aug2015 D1

English (399.6 KB - PDF)View document

Study results

Korean Lastacaft Abstract

English (38.61 KB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs